Choroideremia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Choroideremia Market Outlook
Thelansis’s “Choroideremia Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Choroideremia treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Choroideremia
Overview
Choroideremia
is a rare X-linked recessive genetic disorder characterized by progressive
vision loss, primarily affecting males. It is caused by mutations in the CHM
gene located at Xq21.2, responsible for producing the Rab escort protein-1
(REP-1). In affected males, the condition typically manifests as night
blindness (nyctalopia) during their first or second decade. This is followed by
a narrowing of the peripheral visual field, with a progression from ring-shaped
blind spots (annular scotomas) to a more extensive visual field loss. Visual
acuity impairment becomes noticeable by mid-adulthood. Over time, changes in
the fundus (the back of the eye) are observed, initially showing pigmentary
stippling and focal areas of choroid atrophy in the equatorial fundus. In the
advanced stages, extensive degenerative changes occur in the retinal pigment
epithelium (RPE), with only remnants of the choroidal blood vessels remaining
apparent in the macula, far peripheral retina, and near the optic disc. At this
stage, the sclera becomes visible during fundus examination in areas where the
choroidal and RPE atrophy is complete. Managing Choroideremia involves regular
ophthalmologic examinations to monitor the condition’s progression or the
emergence of cataracts. Additionally, individuals are advised to use
UV-blocking sunglasses to protect their eyes. Unfortunately, there is currently
no available treatment for Choroideremia.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment